| Literature DB >> 19874824 |
Abstract
Glycosphingolipids (GSLs) GM3 (NeuAcalpha3Galbeta4Glcbeta1Cer) and GM2 (GalNAcbeta4[NeuAcalpha3]Galbeta4Glcbeta1Cer) inhibit (i) cell growth through inhibition of tyrosine kinase associated with growth factor receptor (GFR), (ii) cell adhesion/motility through inhibition of integrin-dependent signaling via Src kinases, or (iii) both cell growth and motility by blocking "cross-talk" between integrins and GFRs. These inhibitory effects are enhanced when GM3 or GM2 are in complex with specific tetraspanins (TSPs) (CD9, CD81, CD82). Processes (i)-(iii) occur through specific organization of GSLs with key molecules (TSPs, caveolins, GFRs, integrins) in the glycosynaptic microdomain. Some of these processes are shared with epithelial-mesenchymal transition induced by TGFbeta or under hypoxia, particularly that associated with cancer progression. Copyright 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19874824 PMCID： PMC2867360 DOI： 10.1016/j.febslet.2009.10.065
Source DB: PubMed Journal: FEBS Lett ISSN： 0014-5793 Impact factor: 4.124